Literature DB >> 22290911

False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.

Abel Gómez-Caro1, Marc Boada, Maria Cabañas, Marcelo Sanchez, Pedro Arguis, Francisco Lomeña, Josep Ramirez, Laureano Molins.   

Abstract

OBJECTIVES: To assess the false-negative (FN) rate of positron emission tomography (PET)-chest computed tomography (CT) scan in clinical non-central cIA and cIB non-small-cell lung cancer (NSCLC) for mediastinal staging.
METHODS: Between January 2007 and December 2010, 402 patients with potentially operable NSCLC were assessed by thoracic CT scan and 18-fluoro-2-deoxy-d-glucose PET-CT for mediastinal staging and to detect extrathoracic metastases, of which 153 surgically treated patients (79 cIA and 74 cIB cases) were prospectively included in the study. Central tumours were excluded on the basis of CT scan criteria, defined as contact with the intrapulmonary main bronchi, pulmonary artery, pulmonary veins or the origin of the first segmental branches. CT scan was considered negative if lymph nodes were <1 cm at the smaller diameter. 18FDG PET-CT was considered negative when the high maximum standard uptake value (SUVmax) was <2.5. Non-invasive surgical staging was carried out in this group, and curative resection plus systematic mediastinal dissection was performed except in the event of unexpected oncological contraindication.
RESULTS: Composite non-invasive staging (CT scan, PET-CT) showed a negative predictive value (NPV) of 92% (CI 83.6-96.8) in the cIA group and 85% (CI 74-92) in the cIB group. There were 6 of 79 (7.6%) false-negatives (FNs) in cIA and 11 of 74 (14.8%) in cIB. Multilevel pN2 were detected in four cases, all of them in the cIB group. The most frequently involved N2 was subcarinal (two cases) in cIA and right lower paratracheal (R4) and seven (five cases) in cIB. Occult (pN2) lymph nodes were more frequent in tumour sizes≥5 cm (pT2b, nine cases, four FNs, P=0.03), pN1, adenocarcinoma [excluding minimally invasive adenocarcinoma (MIA) and lepidic predominant growth (LPA)] (P=0.029) and female patients, but no other risk factors for mediastinal metastases were identified (age, clinical stage, tumour location, central or peripheral, P>0.05). Multilevel pN2 was significantly more frequent in the cIB group (P<0.03). In pT≤1 cm (T1a), NPV was significantly better (NPV=100%, P<0.05) than the other subgroups studied (IA>1 cm and IB).
CONCLUSIONS: Composite results for non-invasive mediastinal staging (CT scan, PET-CT) showed 11% of FNs in cI stage (7.6% in non-central cIA and 14.8% in cIB). In tumours≤1 cm, NPV makes surgical staging unnecessary. In women with adenocarcinoma and non-central cIB, however, the high FN rate makes invasive staging necessary, particularly in pT2b to decrease the incidence of unexpected pN2 in thoracotomy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290911     DOI: 10.1093/ejcts/ezr272

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  19 in total

1.  Cons: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Herbert Decaluwé; Christophe Dooms
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Pros: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Carme Obiols; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Variations in positron emission tomography-computed tomography findings for patients receiving neoadjuvant and non-neoadjuvant therapy for non-small cell lung cancer.

Authors:  Jae Kil Park; Jae Jun Kim; Seok Whan Moon
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

Authors:  Eric M Robinson; Ilkka K Ilonen; Kay See Tan; Andrew J Plodkowski; Matthew Bott; Manjit S Bains; Prasad S Adusumilli; Bernard J Park; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

5.  Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis.

Authors:  Tomohiro Haruki; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-05-23       Impact factor: 1.520

Review 6.  Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Transl Lung Cancer Res       Date:  2014-08

7.  Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma.

Authors:  Kun-Han Lue; Sung-Chao Chu; Ling-Yi Wang; Yen-Chang Chen; Ming-Hsun Li; Bee-Song Chang; Sheng-Chieh Chan; Yu-Hung Chen; Chih-Bin Lin; Shu-Hsin Liu
Journal:  Ann Nucl Med       Date:  2021-11-24       Impact factor: 2.668

Review 8.  Present indications of surgical exploration of the mediastinum.

Authors:  Sergi Call; Carme Obiols; Ramon Rami-Porta
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 9.  Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy.

Authors:  David J Heineman; Johannes M Daniels; Wilhelmina H Schreurs
Journal:  Ther Adv Med Oncol       Date:  2017-08-02       Impact factor: 8.168

10.  SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Authors:  G Fernández-Pérez; R Sánchez-Escribano; A M García-Vicente; A Luna-Alcalá; J Ceballos-Viro; R C Delgado-Bolton; J C Vilanova-Busquets; P Sánchez-Rovira; M P Fierro-Alanis; R García-Figueiras; J E Alés-Martínez
Journal:  Clin Transl Oncol       Date:  2017-12-18       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.